



EURIPRED: European Research Infrastructures for Poverty Related Diseases

EURIPRED is a collaborative infrastructure programme with the objective to reinforce the knowledge infrastructure across diseases. The ultimate aim is to speed the development of new tools (vaccines, drugs, microbicides) to combat Tuberculosis, HIV, Malaria and Hepatitis B/ C diseases.

HIV/AIDS, Tuberculosis (TB) and Malaria alone account for about 3.4 million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat these diseases. The existence of a well-developed HIV/ TB/ Malaria infrastructure presents a prime opportunity to address other sexually transmitted diseases such as viral hepatitis efficiently and effectively.

The overall goal of the EURIPRED is to coordinate and integrate international resources into a single specialised infrastructure to support European HIV, TB, Malaria and Hepatitis B/ C virus studies from early drug, vaccine and microbicide discovery to clinical trials. This will be achieved by creating partnerships between European scientists and international research teams from disease endemic countries and strong collaborations between industry and public sector research. Although vaccines, drugs and microbicide research is being conducted in the European Union (EU), so far there was no single European infrastructure that brings international resources and facilities together to develop cost-effective products for the European market.

To underpin this need, EURIPRED will integrate worldwide resources to allow European access to shared clinical material and reference reagents, and training opportunities. This integrated approach will strengthen international cooperation, increase research capacity in EU and developing countries and significantly contribute to the European Research Area (ERA). By minimising fragmentation and duplication of research efforts and pooling fragmented resources EURIPRED can improve European research efficiency and effectiveness.

Partners

EURIPRED's research partners are mainly based in Europe, but also excellent groups from China, Russia and Kenya join the project. They include the following organisations:

1. National Institute of Biological Standards and Control, a centre of the Medicines and Healthcare products Regulatory Agency (NIBSC-MHRA), United Kingdom
2. King's College London (KCL), United Kingdom
3. National center for AIDS/STD control and prevention, Chinese center for disease control and prevention (NCAIDS), China
4. D.I. Ivanovsky Institute of virology of the ministry of health and social development of the Russian Federation
5. Instituto de Salud Carlos III, Spain
6. Kenya Medical Research Institute (KEMRI), Kenya
7. JPT Peptide Technologies GmbH, Germany
8. Polymun Scientific Immunobiologische Forschung GmbH, Austria
9. Leiden University and Medical Centre (LUMC), The Netherlands
10. Icosagen AS, Estonia
11. Tuberculosis Vaccine Initiative (TBVI), The Netherlands
12. University of Lausanne (UNIL), Switzerland
13. Lionex GmbH, Germany
14. University of Oxford (UOXF), United Kingdom
15. London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
16. EATRIS, The Netherlands
17. Federal state budgetary educational institution of higher professional education state university of management (UNICUM), Russian Federation



EURIPRED is co-funded with € 8.5 million by the European Commission. Scientists from 17 research partners in 10 countries collaborate in this programme. The project started in November 2013, is a 4-year project and has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No 312661. The project is coordinated by Dr Mei Mei Ho of NIBSC-MHRA, UK.

www.euripred.eu